Effects of Jiangzhi Ligan Granules combined with simvastatin on hepatic biochemical indexes, leptin and adiponectin in treatment of NAFLD

doi:10.3969/j.issn.1004-583X.2021.01.012

Abstract

Abstract:

Objective To investigate the effect of Jiangzhi Ligan Granules combined with simvastatin on hepatic biochemical indexes, leptin and adiponectin in the treatment of non-alcoholic fatty liver disease (NAFLD). Methods A total of 94 NAFLD patients admitted to our hospital were randomly divided into control group and observation group, with 47 cases in each group. Patients in control group were treated with simvastatin, and those in observation group were treated with Jiangzhi Ligan Granules more. The postoperative efficacy of two groups was analyzed, and the levels of blood lipids, liver biochemistry, leptin (LP), adiponectin (ADPN) and other indicators of two groups were recorded before and after treatment. Results After three months of treatment, the total efficacy rate of patients in observation group was 91.49% (43/47), which was significantly higher than 72.34% (34/47) in control group(P<0.05). TG, TC, LDL-C, ALT, AST, GGT and LP levels in both groups were significantly decreased, while HDL-C and ADPN levels were significantly increased, and the change degree in observation group was significantly higher than that in control group(P<0.05). Conclusion Jiangzhi Ligan Granule combined with simvastatin can significantly improve the balance of blood lipid metabolism and liver function metabolism in NAFLD patients,and effectively regulate the secretion, immunity and insulin functions of the body.

Key words: fatty liver, phytotherapy, simvastatin, laboratory techniques and procedures

CLC Number:

R575.5

Zhang Ying, Wang Chunsheng. Effects of Jiangzhi Ligan Granules combined with simvastatin on hepatic biochemical indexes, leptin and adiponectin in treatment of NAFLD[J]. Clinical Focus, 2021, 36(1): 58-61.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.01.012

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I1/58

Figures/Tables 4

References 15

[1]	杭双熊, 申红玉, 陈敏. 非酒精性脂肪性肝病患者血清SHGB含量与胰岛素敏感性、脂代谢、氧化应激的相关性[J]. 临床和实验医学杂志, 2019,18(01):86-89.
[2]	Yoshiharu T, Yuko M, Kenju S, et al. Non-alcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged japanese men and women[J]. Intern Med, 2017,56(7):763-771. doi: 10.2169/internalmedicine.56.7115 URL
[3]	应晨, 刘彩虹, 胡家安, 等. 阻塞性睡眠呼吸暂停低通气综合征合并非酒精性脂肪性肝病患者血清脂肪代谢相关激素水平的研究[J]. 上海交通大学学报(医学版), 2018,38(10):77-81.
[4]	中华医学会肝病学分会脂肪肝和酒精性肝病学组. 酒精性肝病诊疗指南(2010年修订版)[J]. 中华肝脏病杂志, 2010,18(3):167-170.
[5]	卞晓岚, 郑岚. 降脂利肝颗粒联合辛伐他汀治疗非酒精性脂肪肝的临床疗效观察[J]. 中国药物警戒, 2017,14(2):71-74.
[6]	胡振斌, 陈永洪, 王秀峰, 等. 疏肝降脂颗粒对非酒精性脂肪性肝病患者血清瘦素及脂联素水平的影响[J]. 中西医结合肝病杂志, 2018,28(1):23-24, 62.
[7]	薛建华, 吴香香, 傅益飞, 等. 清肝降脂方联合异甘草酸镁治疗非酒精性脂肪肝临床观察[J]. 中医药信息, 2019,36(3):95-98.
[8]	Hardy T, Zeybel M, Day CP, et al. Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease[J]. Gut, 2017,66(7):1321-1328. doi: 10.1136/gutjnl-2016-311526 URL
[9]	Mofidi F, Poustchi H, Yari Z, et al. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial[J]. Br J Nutr, 2017,117(5):662-668. doi: 10.1017/S0007114517000204 URL
[10]	张广宏, 仇军, 许剑婕. 自拟化瘀降脂汤联合辛伐他汀对高血脂症患者血脂及肝功能指标的影响[J]. 现代中西医结合杂志, 2017,26(2):73-75.
[11]	池肇春. 非酒精性脂肪性肝炎肝硬化发病机制研究进展与展望[J]. 实用肝脏病杂志, 2018,21(2):166-169.
[12]	关婕婷, 刘宝珍, 呼永河, 等. 中西医结合治疗2型糖尿病合并非酒精性脂肪性肝病30例临床研究[J]. 江苏中医药, 2018,50(1):32-34.
[13]	王晓芳, 路振宇, 党殿杰. 自拟化瘀降脂汤联合西药洛伐他汀治疗非酒精性脂肪肝(痰湿内阻证)疗效观察[J]. 四川中医, 2018,36(10):92-94.
[14]	方媛, 刘欣, 史海涛, 等. 甘草酸二铵脂质配位体对非酒精性脂肪性肝病糖脂代谢的影响[J]. 山西医科大学学报, 2017,48(8):783-787.
[15]	盛昭园, 胡粤杭, 刘杰, 等. 健脾疏肝降脂方治疗单纯性肥胖的临床疗效及对瘦素脂联素的影响[J]. 世界中医药, 2017,12(3):120-123.

组别	例数	痊愈	有效	无效	总有效
对照组	47	15(31.91)	19(40.43)	13(27.66)	34(72.34)
观察组	47	21(44.68)	22(46.81)	4(8.51)	43(91.49)
Z值		1.621	0.389	5.817	5.817
P值		0.203	0.533	0.016	0.016

组别	例数	痊愈	有效	无效	总有效
对照组	47	15(31.91)	19(40.43)	13(27.66)	34(72.34)
观察组	47	21(44.68)	22(46.81)	4(8.51)	43(91.49)
Z值		1.621	0.389	5.817	5.817
P值		0.203	0.533	0.016	0.016

组别	例数	TG(mmol/L)		TC(mmol/L)		LDL-C(mmol/L)		HDL-C(mmol/L)
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
对照组	47	2.64±0.59	1.98±0.46^*	6.31±0.84	5.33±0.60^*	4.28±0.69	3.19±0.58^*	1.09±0.33	1.29±0.39
观察组	47	2.69±0.60	1.76±0.33^*	6.2±0.78	4.83±0.52^*	4.34±0.74	2.86±0.54^*	1.11±0.31	1.56±0.41^*
t值		0.407	2.664	0.658	4.317	0.407	2.855	0.303	3.271
P值		0.685	0.009	0.512	0.000	0.685	0.005	0.763	0.002

组别	例数	TG(mmol/L)		TC(mmol/L)		LDL-C(mmol/L)		HDL-C(mmol/L)
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
对照组	47	2.64±0.59	1.98±0.46^*	6.31±0.84	5.33±0.60^*	4.28±0.69	3.19±0.58^*	1.09±0.33	1.29±0.39
观察组	47	2.69±0.60	1.76±0.33^*	6.2±0.78	4.83±0.52^*	4.34±0.74	2.86±0.54^*	1.11±0.31	1.56±0.41^*
t值		0.407	2.664	0.658	4.317	0.407	2.855	0.303	3.271
P值		0.685	0.009	0.512	0.000	0.685	0.005	0.763	0.002

组别	例数	ALT(U/L)		AST(U/L)		GGT(U/L)
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
对照组	47	95.35±17.75	61.47±15.19^*	88.62±17.25	58.77±14.06^*	103.5±24.29	74.43±18.14^*
观察组	47	96.24±18.52	53.63±13.61^*	88.16±17.36	51.91±12.57^*	103±23.61	62.93±16.28^*
t值		0.238	2.635	0.129	2.494	0.101	3.235
P值		0.813	0.010	0.898	0.014	0.920	0.002